These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 2661281

  • 1. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release.
    Pontiroli AE, Calderara A, Maffi P, Bonisolli L, Carenini A, Piatti PM, Monti LD, Gallus G, Pozza G, Illeni MT.
    Diabete Metab; 1989; 15(2):79-84. PubMed ID: 2661281
    [Abstract] [Full Text] [Related]

  • 2. Secondary failure of oral hypoglycaemic agents in lean patients with type 2 diabetes mellitus: insulin sensitivity, insulin response to different stimuli, and the role of cyclic-AMP.
    Pontiroli AE, Caviezel F, Alberetto M, Secchi A, Capra F, Bonisolli L, Calderara A, Pozza G.
    Diabete Metab; 1992; 18(1):25-31. PubMed ID: 1314198
    [Abstract] [Full Text] [Related]

  • 3. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S, Estacio RO, Jeffers B, Schrier RW.
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [Abstract] [Full Text] [Related]

  • 4. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M.
    Ann Acad Med Stetin; 2004 Mar; 50(2):29-39. PubMed ID: 16529163
    [Abstract] [Full Text] [Related]

  • 5. Insulin secretion and immuno-genetic markers in diabetics with 'secondary failure' of oral hypoglycemic agents.
    Colman PG, Harrison LC, Tait BD.
    Aust N Z J Med; 1985 Apr; 15(2):209-12. PubMed ID: 3896215
    [Abstract] [Full Text] [Related]

  • 6. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents.
    Iavicoli M, Cucinotta D, De Mattia G, Lunetta M, Morsiani M, Pontiroli AE, Pozza G.
    Diabet Med; 1988 Dec; 5(9):849-55. PubMed ID: 2976646
    [Abstract] [Full Text] [Related]

  • 7. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
    Lee SW, Lee S, Kim SH, Kim TH, Kang BS, Yoo SH, Lee MK, Koh WJ, Kang WS, Kim HJ.
    Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157
    [Abstract] [Full Text] [Related]

  • 8. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure.
    Zavala AV, Fabiano de Bruno LE, Cardoso AI, Mota AH, Capucchio M, Poskus E, Fainboim L, Basabe JC.
    Diabetologia; 1992 Dec; 35(12):1159-64. PubMed ID: 1478368
    [Abstract] [Full Text] [Related]

  • 9. C-peptide and insulin secretion in diabetes mellitus treated with oral hypoglycaemic agents or diet alone. A 3 years epidemiological cohort study on the Island of Falster, Denmark.
    Nielsen NV, Tronier B.
    Diabetes Res; 1987 Mar; 4(3):135-9. PubMed ID: 3301161
    [Abstract] [Full Text] [Related]

  • 10. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE, Pacchioni M, Piatti PM, Cassisa C, Camisasca R, Pozza G.
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
    Wolffenbuttel BH, Menheere PP, Nijst L, Rondas-Colbers GJ, Sels JP, Nieuwenhuijzen Kruseman AC.
    Neth J Med; 1992 Jun; 40(5-6):277-82. PubMed ID: 1436266
    [Abstract] [Full Text] [Related]

  • 12. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy.
    Greco AV, Caputo S, Bertoli A, Ghirlanda G.
    Horm Metab Res; 1992 Jun; 24(6):280-3. PubMed ID: 1634193
    [Abstract] [Full Text] [Related]

  • 13. A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.
    Scionti L, Misericordia P, Santucci A, Santeusanio F, Brunetti P.
    Acta Diabetol; 1992 Jun; 29(1):20-4. PubMed ID: 1520901
    [Abstract] [Full Text] [Related]

  • 14. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ, Castillo MJ, Lefèbvre PJ.
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [Abstract] [Full Text] [Related]

  • 15. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas.
    Polo V, Saibene A, Pontiroli AE.
    Acta Diabetol; 1998 Apr; 35(1):61-4. PubMed ID: 9625292
    [Abstract] [Full Text] [Related]

  • 16. [Indicators for insulin therapy in late elderly patients with type 2 diabetes mellitus--the relationship between plasma C-peptide on glucagon load test and insulin therapy].
    Miyamoto M.
    Nihon Ronen Igakkai Zasshi; 2009 May; 46(3):244-9. PubMed ID: 19521045
    [Abstract] [Full Text] [Related]

  • 17. Insulin requirement in elderly patients with non-insulin dependent diabetes mellitus (NIDDM).
    Pontiroli AE, Calderara A, Pacchioni M, Cassisa C, Pozza G.
    Aging (Milano); 1989 May; 1(2):147-52. PubMed ID: 2488306
    [Abstract] [Full Text] [Related]

  • 18. Control of non-insulin dependent diabetes is not correlated with endogenous insulin secretion.
    Lev-Ran A, Hwang D, Barseghian G, Hill LR.
    Diabete Metab; 1986 Dec; 12(6):325-8. PubMed ID: 3545932
    [Abstract] [Full Text] [Related]

  • 19. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE, Calderara A, Pacchioni M, Cassisa C, Pozza G.
    Diabete Metab; 1993 Dec; 19(1):30-5. PubMed ID: 8504882
    [Abstract] [Full Text] [Related]

  • 20. C-peptide response to glucagon in patients with non-insulin-dependent diabetes mellitus.
    Juang JH, Huang HS, Huang MJ.
    J Formos Med Assoc; 1992 May; 91(5):491-6. PubMed ID: 1358326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.